PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
186 hedge funds and large institutions have $467M invested in PDL BioPharma, Inc. in 2017 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 63 increasing their positions, 44 reducing their positions, and 13 closing their positions.
138% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 13
45% more capital invested
Capital invested by funds: $322M → $467M (+$145M)
43% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 44
9% more funds holding
Funds holding: 171 → 186 (+15)
37% less call options, than puts
Call options by funds: $450K | Put options by funds: $717K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$8.55M |
| 2 |
Morgan Stanley
New York
|
+$6.49M |
| 3 |
State Street
Boston,
Massachusetts
|
+$5.81M |
| 4 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$3.96M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$9.56M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$4.6M |
| 3 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$3.61M |
| 4 |
BlackRock
New York
|
-$2.18M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2M |
PDLI Hedge Fund Activity: Q3 2017 in Review
186 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q3 2017, worth a combined $467M — up 45% from $322M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new PDLI positions and 13 closed out — a net gain of 18 holders — while 63 added to existing stakes and 44 trimmed.
The largest buyer was Millennium Management, adding an estimated $8.55M. The largest seller was Citadel Advisors, cutting an estimated $9.56M.
- 186 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q3 2017, up from 171 in Q2 2017.
- Funds reported $467M of PDL BioPharma, Inc. stock for Q3 2017, up 45% quarter-over-quarter.
- 31 funds opened new PDL BioPharma, Inc. positions in Q3 2017 and 13 closed out, a net change of +18 holders.
- The largest PDL BioPharma, Inc. buyer in Q3 2017 was Millennium Management, an estimated $8.55M added.
- The largest PDL BioPharma, Inc. seller in Q3 2017 was Citadel Advisors, an estimated $9.56M sold.
Based on aggregated 13F filings for Q3 2017.